San Diego, CA, United States of America

Klaus Wagner



Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2007-2012

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Klaus Wagner: Innovator in Cancer Treatment

Introduction

Klaus Wagner is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of cancer treatment through his innovative research and patented technologies. With a total of 2 patents, Wagner's work focuses on methods to induce apoptosis in cancer cells, which is crucial for developing effective cancer therapies.

Latest Patents

Wagner's latest patents include groundbreaking methods and compositions for inducing apoptosis in cancer cells. One of his notable patents is titled "Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody." This patent describes how anti-DR5 antibody agonists, when combined with apoptosis-inducing agents, can synergistically induce apoptosis in cancer cells. Another significant patent is "Methods and compositions for inducing apoptosis in cancer cells," which focuses on the use of anti-DR4 or anti-DR5 antibody agonists in conjunction with apoptosis-inducing agents to achieve similar results.

Career Highlights

Klaus Wagner is currently associated with Irm LLC, where he continues to advance his research in cancer therapies. His work has garnered attention for its potential to improve treatment outcomes for cancer patients.

Collaborations

Wagner collaborates with esteemed colleagues, including Marc Nasoff and Quinn L Deveraux, who contribute to his research efforts and help drive innovation in the field.

Conclusion

Klaus Wagner's contributions to cancer treatment through his patented methods highlight his role as a key innovator in the medical field. His ongoing research promises to pave the way for more effective cancer therapies in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…